Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Telix Pharmaceuticals Limited has received a consensus rating of "Moderate Buy" from eight analysts, with one sell recommendation, one hold, five buys, and one strong buy.
• The average 12-month price target among brokerages for Telix is $21.00, indicating a potential upside from its current trading price of $9.57.
• Shares of Telix have fluctuated significantly, with a 52-week low of $8.93 and a high of $30.36, while recently down 5.2%.

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $21.00.

A number of research firms recently commented on TLX. Citigroup began coverage on Telix Pharmaceuticals in a research note on Thursday, September 18th. They set a "buy" rating and a $22.00 price objective on the stock. William Blair reiterated an "outperform" rating on shares of Telix Pharmaceuticals in a research report on Wednesday, July 9th. UBS Group reduced their target price on Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Tuesday, September 23rd. HC Wainwright reduced their target price on Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, September 10th. Finally, Wedbush reiterated an "outperform" rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research report on Thursday, August 28th.

Telix Pharmaceuticals Stock Down 5.2%

TLX opened at $9.57 on Monday. Telix Pharmaceuticals has a 52 week low of $8.93 and a 52 week high of $30.36. The business's fifty day simple moving average is $10.47 and its 200 day simple moving average is $14.31.

Hedge Funds Weigh In On Telix Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Private Advisor Group LLC purchased a new position in shares of Telix Pharmaceuticals in the 1st quarter worth about $170,000. IHT Wealth Management LLC purchased a new position in shares of Telix Pharmaceuticals in the 2nd quarter worth about $213,000. Blair William & Co. IL purchased a new position in shares of Telix Pharmaceuticals in the 2nd quarter worth about $217,000. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Telix Pharmaceuticals in the 2nd quarter worth about $297,000. Finally, ABC Arbitrage SA purchased a new position in shares of Telix Pharmaceuticals in the 1st quarter worth about $451,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.